Proposals reviewed in EITN cover a wide range of technologies at different levels of development, including but not limited to MRI (structural, functional, spectroscopic), various molecular imaging systems, MEG, optical, fluorescence imaging, and ultrasound. The unifying feature of EITN is that understanding of the nervous system is important to understanding and evaluating the science proposed; that is, applications address problems specific to the nervous system, or that are strongly shaped by the structural, biological, and functional characteristics of the nervous system. Discovery science as well as hypothesis-driven applications are reviewed.
The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- In vivo, ex vivo, histological, structural, functional and molecular imaging in humans, human neural tissues, animals, and animal neural tissues
- Contrast probe development, including nanoparticles for whole brain imaging
- Creation of imaging database resources; computational approaches and image analysis tools
- Neural network and connectivity mapping; brain atlas creation across multiple modalities and scales
- Mathematical modeling and simulation of neuronal ensembles
- Transcranial magnetic stimulation; focused ultrasound; other non-invasive modalities of experimental and therapeutic brain stimulation
- Imaging and modeling of blood flow: cerebral hemodynamics; cerebrovascular contribution to fMRI
Shared Interests and Overlaps
Imaging Probes and Contrast Agents [IPCA] also reviews applications proposing development of probes, tracers, or contrast agents for use in the nervous system or in neurological disease. The applications are generally reviewed in IPCA when the emphasis is on the early steps such as synthesis, candidate identification, tracer characterization, safety, dosing, and preclinical validation. Applications proposing first in human studies for central nervous system target, or translational applications of new tracers and contrast agents for neuroscience and neurological use would generally be reviewed in EITN.
Emerging Imaging Technologies and Applications [EITA] reviews proposals to refine protocols and optimize imaging systems for specific biological, physiological, and disease targets. If the characteristics of the nervous system are critical to the proposed work, the application will usually be reviewed in EITN. If the emphasis is on development at a level where neuroscience is less central it may be reviewed in EITA.
CClinical Translational Imaging Science [CTIS] reviews developmental imaging proposals in which the work has advanced to the point where testing in humans with clinical outcomes is proposed. When the translational end is neurological, the proposal is likely reviewed in EITN. Non-neurological translational applications are reviewed in CTIS.
EImaging Technology Development [ITD] reviews grant applications that seek to create new imaging technologies or to create new capabilities in existing modalities, sometimes intended for neuroscience problems. When expert knowledge of the nervous system is necessary for evaluating the bioengineering work proposed, the proposal may be reviewed in EITN. Basic engineering for creation of new modalities or new imaging capabilities typically will be reviewed in ITD even if the eventual intended use of the technology is in neuroscience.
Imaging Guided Interventions and Surgery [IGIS] reviews proposals to develop or evaluate new imaging technologies and protocols to target, guide, or control surgeries and medical therapies. Generally, applications to develop an image guided surgical or medical treatment will be reviewed in IGIS, even if the target is a neurological disorder.